LV11992B - METALPIROLIDINYL METHYL ALLEGAL SALT - Google Patents

METALPIROLIDINYL METHYL ALLEGAL SALT Download PDF

Info

Publication number: LV11992B
Authority: LV; Latvia
Prior art keywords: salt; fumarate; compound; fumarate salt; ylmethyl
Prior art date: 1995-05-20

Application number

LVP-97-256A

Other languages

English (en)

Latvian (lv)

Other versions

LV11992A (lv

Inventor

Martin James Wythes

Original Assignee

Pfizer Research And Development Company, N.V./S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-20

Filing date

1997-12-11

Publication date

1998-06-20

1997-12-11 Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.

1998-03-20 Publication of LV11992A publication Critical patent/LV11992A/xx

1998-06-20 Publication of LV11992B publication Critical patent/LV11992B/en

Links

150000003839 salts Chemical class 0.000 title description 5
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 45
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 12
208000019695 Migraine disease Diseases 0.000 claims description 6
239000001530 fumaric acid Substances 0.000 claims description 6
206010027599 migraine Diseases 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 3
238000006243 chemical reaction Methods 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
TZQSNURHFSOKAI-WZGZYPNHSA-N (e)-but-2-enedioic acid;n-methyl-1-[3-[[(2r)-1-methylpyrrolidin-2-yl]methyl]-1h-indol-5-yl]methanesulfonamide Chemical compound OC(=O)\C=C\C(O)=O.C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1C[C@H]1CCCN1C TZQSNURHFSOKAI-WZGZYPNHSA-N 0.000 claims 1
AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 claims 1
AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 18
239000000203 mixture Substances 0.000 description 17
238000009472 formulation Methods 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000012458 free base Substances 0.000 description 12
230000015556 catabolic process Effects 0.000 description 7
238000006731 degradation reaction Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
238000010525 oxidative degradation reaction Methods 0.000 description 4
230000036542 oxidative stress Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
BWQZTHPHLITOOZ-CQSZACIVSA-N n-methyl-1-[3-[[(2r)-1-methylpyrrolidin-2-yl]methyl]-1h-indol-5-yl]methanesulfonamide Chemical compound C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1C[C@H]1CCCN1C BWQZTHPHLITOOZ-CQSZACIVSA-N 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 1
BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-methyl-1H-indole Chemical class C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000013590 bulk material Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000011170 pharmaceutical development Methods 0.000 description 1
-1 phosphorio Chemical class 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000004441 surface measurement Methods 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Pyrrole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

LVP-97-256A 1995-05-20 1997-12-11 METALPIROLIDINYL METHYL ALLEGAL SALT LV11992B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9510223.2A GB9510223D0 (en)	1995-05-20	1995-05-20	Therapeutic agent
PCT/EP1996/001560 WO1996036632A1 (fr)	1995-05-20	1996-04-10	Sel de methylpyrrolidinylindole

Publications (2)

Publication Number	Publication Date
LV11992A LV11992A (lv)	1998-03-20
LV11992B true LV11992B (en)	1998-06-20

Family

ID=10774766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-97-256A LV11992B (en)	1995-05-20	1997-12-11	METALPIROLIDINYL METHYL ALLEGAL SALT

Country Status (41)

Country	Link
US (1)	US5994387A (fr)
EP (1)	EP0827503B1 (fr)
JP (1)	JP3233940B2 (fr)
KR (1)	KR100295255B1 (fr)
CN (1)	CN1063175C (fr)
AP (1)	AP738A (fr)
AR (1)	AR003949A1 (fr)
AT (1)	ATE194986T1 (fr)
AU (1)	AU701154B2 (fr)
BG (1)	BG63046B1 (fr)
BR (1)	BR9610858A (fr)
CA (1)	CA2219631C (fr)
CO (1)	CO5040221A1 (fr)
CZ (1)	CZ287939B6 (fr)
DE (1)	DE69609504T2 (fr)
DK (1)	DK0827503T3 (fr)
DZ (1)	DZ2034A1 (fr)
ES (1)	ES2148753T3 (fr)
GB (1)	GB9510223D0 (fr)
GR (1)	GR3034290T3 (fr)
HR (1)	HRP960223B1 (fr)
HU (1)	HU217657B (fr)
IL (1)	IL118239A (fr)
IS (1)	IS1908B (fr)
LV (1)	LV11992B (fr)
MA (1)	MA23876A1 (fr)
MX (1)	MX9708966A (fr)
MY (1)	MY132066A (fr)
NO (1)	NO312068B1 (fr)
NZ (1)	NZ306448A (fr)
OA (1)	OA10747A (fr)
PL (1)	PL183142B1 (fr)
PT (1)	PT827503E (fr)
RU (1)	RU2161618C2 (fr)
SK (1)	SK281782B6 (fr)
TN (1)	TNSN96074A1 (fr)
TR (1)	TR199701397T1 (fr)
UA (1)	UA44320C2 (fr)
WO (1)	WO1996036632A1 (fr)
YU (1)	YU29496A (fr)
ZA (1)	ZA963938B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9825988D0 (en) *	1998-11-27	1999-01-20	Pfizer Ltd	Indole derivatives
US20100266638A1 (en) *	2004-02-26	2010-10-21	Allergan, Inc.	Headache treatment method
JP2015524400A (ja) *	2012-07-19	2015-08-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3906406C1 (fr) *	1989-03-01	1990-10-25	Goedecke Ag, 1000 Berlin, De
US5545644A (en) *	1990-10-15	1996-08-13	Pfizer Inc.	Indole derivatives
HU225055B1 (en) *	1990-10-15	2006-05-29	Pfizer	Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds
AP486A (en) *	1993-04-27	1996-04-16	Pfizer	Indole derivatives.

1995
- 1995-05-20 GB GBGB9510223.2A patent/GB9510223D0/en active Pending
1996
- 1996-04-10 DE DE69609504T patent/DE69609504T2/de not_active Expired - Fee Related
- 1996-04-10 CZ CZ19973648A patent/CZ287939B6/cs not_active IP Right Cessation
- 1996-04-10 UA UA97126158A patent/UA44320C2/uk unknown
- 1996-04-10 JP JP53448896A patent/JP3233940B2/ja not_active Expired - Fee Related
- 1996-04-10 KR KR1019970708280A patent/KR100295255B1/ko not_active Expired - Fee Related
- 1996-04-10 ES ES96912013T patent/ES2148753T3/es not_active Expired - Lifetime
- 1996-04-10 CN CN96194043A patent/CN1063175C/zh not_active Expired - Fee Related
- 1996-04-10 NZ NZ306448A patent/NZ306448A/xx unknown
- 1996-04-10 RU RU97120998/04A patent/RU2161618C2/ru not_active IP Right Cessation
- 1996-04-10 US US08/952,792 patent/US5994387A/en not_active Expired - Fee Related
- 1996-04-10 PL PL96323143A patent/PL183142B1/pl unknown
- 1996-04-10 SK SK1541-97A patent/SK281782B6/sk unknown
- 1996-04-10 HU HU9801761A patent/HU217657B/hu not_active IP Right Cessation
- 1996-04-10 DK DK96912013T patent/DK0827503T3/da active
- 1996-04-10 PT PT96912013T patent/PT827503E/pt unknown
- 1996-04-10 BR BR9610858A patent/BR9610858A/pt not_active Application Discontinuation
- 1996-04-10 MX MX9708966A patent/MX9708966A/es not_active IP Right Cessation
- 1996-04-10 AU AU55005/96A patent/AU701154B2/en not_active Ceased
- 1996-04-10 CA CA002219631A patent/CA2219631C/fr not_active Expired - Fee Related
- 1996-04-10 TR TR97/01397T patent/TR199701397T1/xx unknown
- 1996-04-10 WO PCT/EP1996/001560 patent/WO1996036632A1/fr not_active Ceased
- 1996-04-10 AT AT96912013T patent/ATE194986T1/de not_active IP Right Cessation
- 1996-04-10 EP EP96912013A patent/EP0827503B1/fr not_active Expired - Lifetime
- 1996-04-11 AP APAP/P/1996/000801A patent/AP738A/en active
- 1996-05-10 AR ARP960102519A patent/AR003949A1/es unknown
- 1996-05-13 IL IL11823996A patent/IL118239A/xx not_active IP Right Cessation
- 1996-05-16 YU YU29496A patent/YU29496A/sh unknown
- 1996-05-16 HR HR960223A patent/HRP960223B1/xx not_active IP Right Cessation
- 1996-05-17 TN TNTNSN96074A patent/TNSN96074A1/fr unknown
- 1996-05-17 MA MA24243A patent/MA23876A1/fr unknown
- 1996-05-17 CO CO96025158A patent/CO5040221A1/es unknown
- 1996-05-17 MY MYPI96001888A patent/MY132066A/en unknown
- 1996-05-17 ZA ZA9603938A patent/ZA963938B/xx unknown
- 1996-05-18 DZ DZ960077A patent/DZ2034A1/fr active
1997
- 1997-10-30 IS IS4605A patent/IS1908B/is unknown
- 1997-11-13 NO NO19975210A patent/NO312068B1/no not_active IP Right Cessation
- 1997-11-18 BG BG102053A patent/BG63046B1/bg unknown
- 1997-11-20 OA OA70132A patent/OA10747A/en unknown
- 1997-12-11 LV LVP-97-256A patent/LV11992B/en unknown
2000
- 2000-08-30 GR GR20000401977T patent/GR3034290T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
MY132066A (en)	2007-09-28
IL118239A (en)	2000-10-31
LV11992A (lv)	1998-03-20
AP738A (en)	1999-03-23
KR100295255B1 (ko)	2001-08-07
UA44320C2 (uk)	2002-02-15
IS1908B (is)	2003-12-31
CZ364897A3 (cs)	1998-11-11
HK1017884A1 (en)	1999-12-03
IL118239A0 (en)	1996-09-12
MA23876A1 (fr)	1996-12-31
BR9610858A (pt)	1999-07-13
ZA963938B (en)	1997-11-17
HRP960223A2 (en)	1997-10-31
DK0827503T3 (da)	2000-11-20
AR003949A1 (es)	1998-09-30
SK281782B6 (sk)	2001-07-10
PL323143A1 (en)	1998-03-16
CO5040221A1 (es)	2001-05-29
RU2161618C2 (ru)	2001-01-10
CA2219631C (fr)	2001-01-23
JPH10506639A (ja)	1998-06-30
GB9510223D0 (en)	1995-07-19
EP0827503B1 (fr)	2000-07-26
US5994387A (en)	1999-11-30
PL183142B1 (pl)	2002-05-31
HUP9801761A3 (en)	1999-06-28
TNSN96074A1 (fr)	2005-03-15
HU217657B (hu)	2000-03-28
NO975210D0 (no)	1997-11-13
ES2148753T3 (es)	2000-10-16
NZ306448A (en)	1998-10-28
BG63046B1 (bg)	2001-02-28
KR19990014934A (ko)	1999-02-25
HRP960223B1 (en)	2000-12-31
GR3034290T3 (en)	2000-12-29
ATE194986T1 (de)	2000-08-15
PT827503E (pt)	2000-11-30
DE69609504D1 (de)	2000-08-31
DZ2034A1 (fr)	2002-07-21
BG102053A (en)	1998-06-30
JP3233940B2 (ja)	2001-12-04
DE69609504T2 (de)	2000-12-14
CN1063175C (zh)	2001-03-14
OA10747A (en)	2002-12-11
HUP9801761A2 (hu)	1999-05-28
CZ287939B6 (cs)	2001-03-14
SK154197A3 (en)	1999-01-11
WO1996036632A1 (fr)	1996-11-21
AP9600801A0 (en)	1996-04-30
MX9708966A (es)	1998-03-31
YU29496A (sh)	1998-12-23
AU5500596A (en)	1996-11-29
IS4605A (is)	1997-10-30
NO975210L (no)	1997-11-13
NO312068B1 (no)	2002-03-11
EP0827503A1 (fr)	1998-03-11
AU701154B2 (en)	1999-01-21
CN1185152A (zh)	1998-06-17
CA2219631A1 (fr)	1996-11-21
TR199701397T1 (xx)	1998-03-21

Publication	Publication Date	Title
EP4073036B1 (fr)	2023-11-01	Forme cristalline d'un dérivé d'acide 7h-benzo[7]annulène-2-carboxylique
CS228119B2 (en)	1984-05-14	Production of n2-arylsulphonyl-l-argininamides
SI20473A (sl)	2001-08-31	Tienilazolilalkoksietanamini, njihova priprava in njihova uporaba kot zdravila
US20200283371A1 (en)	2020-09-10	Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide or of derivative thereof and method for preparing same
CA2047880A1 (fr)	1992-01-27	Derives de benzimidazole, leur preparation, et leur application en tant que medicaments
US5994387A (en)	1999-11-30	Pyrrolidinyl methyl indole salt
US12492192B2 (en)	2025-12-09	Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
WO2014013465A2 (fr)	2014-01-23	Sels et hydrates de composés antipsychotiques
AU657591B2 (en)	1995-03-16	Stable salts of (+)-(1S,2R)-2-((N-(2-hydroxylamino-2-oxoethyl)-N-methyl- amino)carbonyl)cyclohexane-1-carboxylic acid, process for their preparation and pharmaceutical compositions containing them
EA001363B1 (ru)	2001-02-26	Кристаллический фармацевтический продукт
US5744495A (en)	1998-04-28	N, N-diethyl-8, 8-dipropyl-2-azaspiro 4.5! decane-2-propanamine
US10329264B2 (en)	2019-06-25	Process for the preparation of isocarboxazid
TWI876245B (zh)	2025-03-11	(2R, 3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新穎酸加成鹽及晶形
EP4574835A1 (fr)	2025-06-25	Forme amorphe de dérivé de cétoamide et procédé pour la préparer
KR102209701B1 (ko)	2021-01-29	토파시티닙의 신규한 결정형 형태 및 이의 제조방법
WO2025017454A1 (fr)	2025-01-23	Dispersions solides stables de salcaprozate avec divers ingrédients pharmaceutiques actifs
CN120040430A (zh)	2025-05-27	一种取代四氢呋喃衍生物的可药用盐、其结晶形式及用途
CN120040429A (zh)	2025-05-27	一种取代四氢呋喃衍生物的结晶形式及其用途
WO2008092816A2 (fr)	2008-08-07	Nouvelles formes polymorphes de n-pipéridino-5-(4-chlorophényl)-1(2,4-dichlorphényl)-4-méthyl-3-pyrazolecarboxamide
WO2005023789A1 (fr)	2005-03-17	Sel phosphorique de l'acide (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoique
WO2005023790A1 (fr)	2005-03-17	Sel sodique d'acide (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoique